



RECORD/

05-09-2003



Our Ref.: 620-161

Commissioner of Patents and Trademarks
Box Assignment, Washington, D.C. 20231

102445173

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies): 5-5-03
Cancer Research Ventures Limited
5 Alfred Place
London, United Kingdom WC1E 7EB

Additional name/s of conveying party/ies attached? ☐

3. Nature of conveyance:
☐ Assignment ☐ Merger
☐ Security Assignment ☐ Change of Name
☒ Other Deed of Assignment

Execution Date: October 31, 2002

2. Name and address of receiving party(ies):
Name: Cancer Research Campaign Technology Limited
Internal Address: _____
Street Address: 61 Lincoln's Inn Fields

City: London
State/Country: United Kingdom
Zip: WC2A 3PX

Additional name/s & address/es attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s):
If this document is being filed together with a new application, the execution date of the application is: _____

A. Patent Application No(s).
(1) 09/922,652
(2) 09/898,461
(3) _____

B. Patent No(s).
(1) 6,303,323
(2) _____
(3) _____

Additional numbers attached ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: B. J. Sadoff
Internal Address: _____
Street Address: Nixon & Vanderhye P.C.
1100 North Glebe Road
8th Floor
City: Arlington State: VA Zip: 22201

6. Total number of applications & patents involved: 3

7. Total fee (37 CFR 3.41) \$ 120.00
☐ Enclosed

☒ Authorized to be charged to deposit account #14-1140
Previously paid December 4, 2002 - post card receipt attached.

8. The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper thereafter filed in this application by this firm) to our Account No. 14-1140.

DO NOT USE THIS SPACE

9. Statements and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

B. J. Sadoff
Name of Person Signing
Reg. No. 36,663

B. J. Sadoff
Signature

May 5, 2003
Date

Total number of pages including original cover sheet, attachments, and document: [19]

DATED 31 OCTOBER 2002


CANCER RESEARCH VENTURES LIMITED

- and -

CANCER RESEARCH TECHNOLOGY LIMITED

INTELLECTUAL PROPERTY ASSIGNMENT

I certify that this is a true copy of the original document.


C.D.G. Pickering
Solicitor of the Supreme Court of England and Wales
(Roll number 199245)

THIS DEED OF ASSIGNMENT is made the 31~~st~~ day of OCTOBER 2002

BETWEEN:

- (1) **CANCER RESEARCH VENTURES LIMITED** a company registered in England (registered number 3521378) whose registered office is situated at 5 Alfred Place, London WC1E 7EB (the "Assignor"); and
- (2) **CANCER RESEARCH TECHNOLOGY LIMITED (formerly known as CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED)** a company registered in England (registered number 1626049) whose registered office is situated at 61 Lincoln's Inn Fields, London WC2A 3PX (the "Assignee")

WHEREAS:

In accordance with an agreement 30 September 2002 made between the Assignor and the Assignee, it was agreed that all of the Assignor's right, title and interest in and to the Assignor Intellectual Property (as defined below) shall be assigned to Assignee, subject to and with the benefit of any encumbrances (including any licence or other agreements) relating to such Assignor Intellectual Property, on the following terms and conditions.

NOW THIS DEED WITNESSES as follows:

1. DEFINITIONS AND INTERPRETATION

- 1.1 In this Assignment and in the Schedule to this Agreement the following words and phrases shall have the following meanings unless the context requires otherwise:

"Assignment" means this deed of assignment and any and all schedules, appendices and other addenda to it as may be varied from time to time in accordance with the provisions of this assignment.

"Assignor Intellectual Property" means the Assignor Patent Rights, but excluding any right that is by way of or in the nature of a licence.

"Assignor Patent Rights" means the patents and patent application particulars of which are set out in Schedule 1 together with any Patent Rights which claim priority or are derived therefrom or which claim the same subject matter as such patents and patent applications.

"Parties" means the Assignors and Assignee and "Party" shall be construed accordingly.

"Patent Rights" means any patent applications, patents, author certificates, inventor certificates, utility certificates and all foreign counterparts of them and includes all divisions, renewals, continuations, continuations-in-

part, extensions, reissues, substitutions, confirmations, registrations, revalidations and additions of or to them, as well as any SPC, or like form of protection.

"SPC"

means a right based on a patent pursuant to which the holder of the right is entitled to exclude third parties from using, making, having made, selling or otherwise disposing or offering to dispose of, importing or keeping the product to which the right relates, such as Supplementary Protection Certificates in Europe, and any similar right anywhere in the world.

- 1.2 The headings used in this Assignment shall not affect its interpretation except in the Schedule.

2. ASSIGNMENT

- 2.1 The Assignor HEREBY ASSIGNS to the Assignee absolutely, subject to and with the benefit of any and all encumbrances (including without limitation any licence or other agreements), all of its right, title and interest throughout the world in and to:

2.1.1 the Assignor Intellectual Property (including all right, title and interest in Canada and the United States of America and all other countries of the world);

2.1.2 all rights and powers arising or accrued from the Assignor Intellectual Property including the right to recover and take all such proceedings as may be necessary for the recovery of damages and/or other remedies in respect of all infringements whether committed before or after the date of this Assignment and to have the benefit of any remedy obtained on any infringement or alleged infringement before the date of this Assignment; and

2.1.3 the right to apply for, prosecute and to obtain Patent Rights in any part of the world (including but not limited to Canada and the United States) in respect of the Assignor Patent Rights and to claim priority from the date of any application embodied in the Assignor Patent Rights, with the intent that the grant of any patents or similar protection shall be in the name of and vest in Assignee.

- 2.2 The Assignor hereby requests the relevant authorities in all countries of the world to issue any patents granted for the invention described in the Assignor Patent Rights in the name of Assignee or its successors or assigns in accordance with this Assignment.

3. FURTHER ASSURANCE

- 3.1 At the request and cost of the Assignee and without unreasonable delay, the Assignor shall sign, execute, make and do all such further deeds, documents, acts and things as Assignee may reasonably require to give effect to this Assignment and to allow Assignee to enjoy the full benefit of the rights hereby assigned.

4. GENERAL

- 4.1 Failure by any of the parties to enforce at any time or for any period any one or more of the terms or conditions of this Assignment shall not be a waiver of them or the rights at any time subsequently to enforce all terms and conditions of this Assignment.
- 4.2 This Assignment shall be binding upon the Assignors' successors and shall enure to the benefit of any successors and/or assigns of Assignee and references to a Party shall include reference to its successors and/or assigns.

5. GOVERNING LAW AND JURISDICTION

- 5.1 All matters relating to this Assignment shall be governed by English law and the Parties submit to the exclusive jurisdiction of the courts of England and Wales.

SCHEDULE 1

Assignor Patent Rights

PROJECT	PATENT TITLE	CRV FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
Regent 4	Improvements Relating to Cancer Therapy	016/0005 - Mewburn Ellis	US	09/898461 (Publication no.: US 2002 - 0090709-A1)	5/7/01	Priority Application
Regent 5	Improved Antibodies	016/0007 - JA Kemp & Co US	US	60/392,354	1/7/02	Priority
Bernards 1	Expression System	037/0018 - Kilburn & Strode	UK	0130955.8	24/12/01	Priority
			UK	0218556.9	9/8/02	Application
			US	60/377482	2/5/02	Application
			US	TBC	9/8/02	Application
Blow 1	Assay Methods	051/0005 - Mewburn Ellis	UK	0209508.1	25/4/02	Priority
Cooper 2	H1B01	008/0038 - Mewburn Ellis	UK	0127344.0	14/11/01	Priority

CDGP/005 / 0012 A

PROJECT	PATENT TITLE	CRV FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
Darling 2	Materials & methods relating to Increasing Retroviral Titre	060/0006 - Mewburn Ellis	UK	009619.8	18/4/00	Nationals
			UK	013731.6	14/2/01	Priority
			PCT	PCT/GB01/01261	22/3/01	PCT
			AU	TBC	18/11/02	Application
			CA	TBC	18/10/02	Application
			CN	TBC	18/10/02	Application
			EP	TBC	18/11/02	Application
			HK	TBC	"	Application
			INDIA	TBC	18/11/02	Application
			JP	TBC	18/10/02	Application
			KR	TBC	18/11/02	Application
			NZ	TBC	18/11/02	Application
			SG	TBC	18/10/02	Application
			US	TBC	18/10/02	Application
DMXAA 1	Compounds having anti- tumor & antibacterial properties	019/0003 - D Young & Co.	AT	EP0278176	22/12/87	Nationals
			BE	EP0278176	22/12/87	Granted
			CH	EP0278176	22/12/87	Granted
			DE	P3789299.1	22/12/87	Granted
			ES	EP0278176	22/12/87	Granted
			FR	EP0278176	22/12/87	Granted
			GR	3012092	22/12/87	Granted
			HK	1000801	10/12/97	Granted
			IT	EP0278176	22/12/87	Granted
			JP	325109/87	22/12/87	Granted
			LU	EP0278176	22/12/87	Granted
			NL	EP0278176	22/12/87	Granted
			SE	EP0278176	22/12/87	Granted
			UK	EP0278176	22/12/87	Granted
			US	07/912,466 (US5281620)	13/7/92	Granted

CDGP

PROJECT	PATENT TITLE	CRV FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
DMIXAA 2	Cancer Therapy	019/0003 - D Young & Co.	NZ PCT	336259 PCT/NZ00/00098 (WO00/76597)	14/6/99 14/6/00	Nationals Priority PCT
			EP JP NZ US	942571.1 01-502830 516564 10/014887	8/1/02 14/12/01 11/1/02 11/12/01	Application Application Application Application
DMIXAA 3	Combination therapy for cancer	019/0003 - D Young & Co.	NZ JP US EP	NZ503199 232871/00 09/774,002 01307370.5	3/3/00 1/8/00 31/1/01 30/8/01	Nationals Priority Application Application Application
DMIXAA 4	Cancer Therapy by combination therapy	019/0003 - D Young & Co.	NZ PCT	NZ 506060 PCT/NZ01/00154 (WO02/09700)	28/7/00 22/7/01	PCT Priority PCT
DMIXAA 5	Anticancer compounds	019/0003 - D Young & Co.	UK PCT	01212851.1 PCT/GB02/004025	3/9/01 3/9/02	PCT Priority PCT
DMIXAA 6	Combination with NSAIDs	019/0003 - D Young & Co.	UK	0206839.3	22/3/02	Priority Priority

COGP/005 / 0012 A

PROJECT	PATENT TITLE	CRV FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
Gaken 1	Materials & Methods relating to the expression of genes - Fusogene	060/0005 - Newburn Ellis	UK	9810999.4	21/5/98	Nationals
			PCT	PCT/GB99/01609	21/5/99	Priority
			AU	40508/00	21/5/99	Application
			CA	2333144	27/12/00	Application
			CN	99808292.9	5/1/01	Application
			EP	99923745.6	31/5/99	Application
			HK	01103431.0	17/5/01	Application
			INDIA	IN/PCT/2000/00627	12/12/00	Application
			INDONESIA	W-20002666	20/12/00	Application
			JP	2000-549741	21/11/00	Application
			KR	TBC	21/11/00	Application
			NZ	508863	14/12/00	Application
			SG	200006708-2	21/11/00	Application
			US	09/700731	20/11/00	Application
Glover 1	Inhibiting Gene Expression (RNAi)	047/0005 - Kilburn & Strode	UK	GB 9927444.1	19/11/99	Nationals
			PCT	PCT/GB00/04404 (WO01/36646)	17/11/00	Priority
			AU	14065/01	23/5/02	Application
			CA	TBC	TBC	Application
			EP	00976188.3	17/11/00	Application
			IL	149666	14/5/02	Application
			JP	2001-538524	20/5/02	Application
			MX	PA/a/2002/005013	17/5/02	Application
			NO	2002 2359	TBC	Application
			NZ	519325	31/5/02	Application
			PL	TBC	17/5/02	Application
			SG	200203380-1	12/6/02	Application
			US	10/150426	17/5/02	Application
			ZA	2002/3816	14/5/02	Application

CDGP/005 / 6012 A

PROJECT	PATENT TITLE	CRV FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
Graham 6	Chemokine and uses thereof	009/0008 - Mewburn Ellis	UK	0207624.8	02/04/02	Priority Priority PCT
Guldberg 1	Materials and methods relating to nucleic acid amplification and profiling	023/0004 - Mewburn Ellis	UK UK PCT	0025913.5 0107547.2 PCT/GB01/04707 (WO02/34942)	23/10/00 26/3/01 23/10/01	Priority Priority Application PCT
Hadfield 1	Materials & methods for synthesising stilbenes	010/0022 - Mewburn Ellis	UK PCT	0031263.7 PCT/GB01/05534	21/12/00 14/12/01	Priority Application PCT
Hadfield 2	Substituted Stilbenes & their reactions	010/0023 - Mewburn Ellis	UK UK PCT	0031262.9 0100295.5 PCT/GB01/05702	21/12/00 5/1/01 20/12/01	Priority Priority Application PCT
Jackman 2	Anti-Cancer Compounds CB300919 Series of Compounds	008/0022 - JA Kemp & Co	UK PCT AU CA EP JP US	GB 9904275.6 PCT/GB00/00655 (WO00/50417) 26838/00 2364708 00905212.7 2000-60098 09/914,010	24/2/99 24/2/00 31/8/01 21/8/01 16/8/01 24/8/01 19/10/01	Priority Application Application Application Application Application Application

CDGP/005 / 0012 A

PROJECT	PATENT TITLE	CRV FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
Luskey 3	Determination of Cellular Growth Abnormality	047/0007 - Newburn Ellis				Nationals
			UK	9722217.8	21/10/97	Priority
			UK	9724134.3	14/11/97	Priority
			UK	9804156.9	26/2/98	Priority
			UK	9810560.4	15/5/98	Priority
			UK	9817075.6	5/8/98	Priority
			PCT	PCT/GB98/03153 (WO99/21014)	21/10/98	Published 29/4/99
			AU	9895502	21/10/98	Application
			CA	230872	21/10/98	Application
			EP	98949123.8	21/10/98	Application
Marshall 2	MARK	008/0025 - Newburn Ellis	JP	11-523482	21/10/98	Application
			NZ	508996	21/10/98	Granted
			UK	2332515B	21/10/98	Granted
			US	60/071245	22/12/97	Provisional
			US	60/086885	27/5/98	Provisional
			US	60/095966	16/10/01	Provisional
			US	09/175947 (6303323B1)	21/10/98	Granted
			US	09/922652	8/7/01	Divisional
						PCT
			UK	0106641.4	16/3/01	Priority
			PCT	PCT/GB02/01282	18/3/02	PCT

PROJECT	PATENT TITLE	CRV FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
Minucci 1	Materials and methods relating to the treatment of leukaemias	027/0007 - Mewburn Ellis	UK PCT	00072173 PCT/GB01/01274	24/3/00 22/3/01	PCT Priority PCT
Neidle 6	Therapeutic Acridone and Acridine Compounds	008/0029 - Mewburn Ellis	US PCT	US 60/216624 PCT/GB01/03046 (WO02/08193)	7/7/00 6/7/01	PCT Priority Application
Neidle 7	Therapeutic Acridone and Acridine Compounds	008/0039 - Mewburn Ellis	US	60/347899	5/1/02	Priority Priority
Neidle 8	Crystal Structure of G- Quadruplex	008/0042 - Mewburn Ellis	UK	0207623.0		Priority Priority
Palicci 1	Materials and methods relating to the effects of P66 expression	027/0006 - Mewburn Ellis	UK PCT AU CA EP JP US	9906515.3 PCT/GB00/01079 (WO00/36886) 0033124 2367464 00911131.1 2000-606745 09/937182	22/3/99 22/3/00 22/3/00	Priority PCT Application Application Application Application Application

CDGP/005 / 0012 A

CDG

PROJECT	PATENT TITLE	CRV FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
Plasterk 1	Vectors and Methods for Providing Cells with Additional Nucleic Acid Material Integrated in the Genome of Said Cells	037/0010 - Vereingde				Nationals
			EP	EP96200298.6	9/2/96	Priority
			PCT	PCT/NL97/00040	7/2/97	Application
				(WO97/29202)		
			EP	97902729.9	9/2/98	Application
			AU	16746/97	23/7/98	Application
			CA	2244812	31/7/98	Application
			JP	9-528410	7/8/98	Application
			US	08/909786	12/8/97	Withdrawn
			US(CIP)	09/317062 - 6,051,430	12/8/97	Granted
Plasterk 2	Vectors and Methods for Providing Cells with Additional Nucleic Acid Material Integrated in the Genome of Said Cells	037/0010 - Vereingde	US	09/117985	7/8/98	Withdrawn
			US(CIP)	09/731289	6/12/00	Application
						Nationals
			PCT	PCT/NL98/00456	11/8/98	Application
				(WO99/07871)		
			AU	87528/98	17/5/99 & 30/6/99	Application
			CA	2301198	17/5/99	Application
			EP	98939015.8	30/6/99	Application
			JP	TBC	TBC	Application
			MX	1495	11/2/00	Application
			NZ	502894	16/2/00	Application
			US	09/502624	11/2/00	Application

PROJECT	PATENT TITLE	CRV FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
Schellens 1	BCRP	037/0016 - Nederlandsch Octrooibureau				Nationals
			NL	1012066	17/5/99	Priority
			NL	1012481	30/6/99	Priority
			PCT	PCT/NL00/00331	17/5/00	Application
			EP	009317207	TBC	Application
			US	09/988285	TBC	Application
Shamkhani 1	Material and methods relating to the increase of protein activity	078/0003 - Mewburn Ellis				PCT
			UK	0015426.0	24/6/00	Priority
			PCT	PCT/GB01/02810	25/6/01	Application
Shamkhani 3	Multimeric Proteins	078/0008 - JA Kemp & Co				Priority
			UK	0125093.5	18/10/01	Priority
Splits 1	Stat 5 materials and methods relating to the production and maintenance of cell lines	037/0017 - Mewburn Ellis				Priority
			UK	0130223.1	18/12/01	Priority
			UK	0206085.1	14/3/02	Priority
			UK	0206086.1	14/3/02	Priority

CDGP/005 / 0012 A

PROJECT	PATENT TITLE	CRV FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
Stevens I	Benzothiazole Compounds for Use in Therapy 2-aryl benzothiazole compounds CJM126	071/0004 - Wilson Gunn Skerrett	UK	GB 9317949.7	28/8/93	Priority
			PCT	PCT/GB94/01883 (WO95/06469)	30/8/94	Application
			AT	182077	30/8/94	Granted
			BE	0721336	30/8/94	Granted
			CH	0721336	30/8/94	Granted
			DE	69419517	30/8/94	Granted
			DK	0721336	30/8/94	Granted
			ES	ES2133571T3	30/8/94	Granted
			FR	0721336	30/8/94	Granted
			GR	0721336	30/8/94	Granted
			IE	0721336	30/8/94	Granted
			IT	0721336	30/8/94	Granted
			LU	0721336	30/8/94	Granted
			MC	0721336	30/8/94	Granted
			NL	0721336	30/8/94	Granted
			PORTUGAL	0721336	30/8/94	Granted
			SE	0721336	30/8/94	Granted
			UK	0721336	30/8/94	Granted
			AU	690577	30/8/94	Granted
			CA	2170508	30/8/94	Application
			JP	508001/1995	30/8/94	Application
			US	5874431	28/2/96	Granted

CJM126A

CD

PROJECT	PATENT TITLE	CRV FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
Stevens 2	Benzazole Compounds 2- Arylbenzazole Compounds	071/0005 - Wilson Gunn Skerrett	UK	GB 9503946.7	28/2/95	Nationals
			PCT	PCT/GB96/00440	28/2/96	Priority
			EP	96904181.3	28/2/96	Application
			AU	711052	28/2/96	Granted
			CA	2213737	28/2/96	Application
			JP	526096/1996	28/2/96	Application
			US	6034246	28/2/97	Granted
Stevens 4	2 Arylbenzazole Compounds	071/0007 - Wilson Gunn Skerrett	UK	GB 9919673.5	20/8/99	Nationals
			PCT	PCT/GB00/03210	21/8/00	Priority
				(WO01/14354)		Application
			AU	67085/00	21/8/00	Application
			CA	2382406	21/8/00	Application
			EP	00954726.6	21/8/00	Application
Stevens 5	Therapeutic Polycyclic Compounds	071/0008 - Mewburn Ellis	JP	51844/2001	19/2/02	Application
			US	10/069018	20/2/02	Application
						PCT
			US	US 60/239267	12/10/00	Priority
			PCT	PCT/GB01/04557	12/10/01	Application
						PCT
Stevens 6	Therapeutic Compounds	071/0009 - Mewburn Ellis	UK	116594.3	6/7/01	Priority
			PCT	PCT/GB02/003097	5/7/02	Application

COGN

PROJECT	PATENT TITLE	CRV FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
Stevenson 1	Improvements in or relating to immune response modification	078/0005 - Mewburn Ellis	UK PCT	9220808.1 PCT/GB93/02054 (WO94/08008) 48324/93 - 685399 2,145,064 93921048.0 508859/1994 08/896,535	2/10/92 4/10/93 4/10/93 4/9/93 4/10/93 4/10/93 18/7/97	Nationals Priority Application Granted Application Application Application Application
Stevenson 2	Materials and methods relating to immune Responses	078/0006 - Mewburn Ellis	UK PCT	0009470.6 PCT/GB01/01719 (WO01/79510)	17/4/00 17/4/01	Nationals Priority Application
Stevenson 3	Materials and methods relating to fusion of proteins for inducing on Immune Response	078/0009 - Mewburn Ellis	EP JP US	TBC TBC TBC	16/10/02 16/10/02 16/10/02	Application Application Application PCT
Stevenson 4	Materials and methods relating to the treatment of lymphoma	078/0009 - Mewburn Ellis	UK PCT	0028319.2 PCT/GB01/05142 (WO02/40513)	20/11/00 20/11/01	Priority Application Priority
			UK	0205395.7	7/3/02	Priority

CDGP

PROJECT	PATENT TITLE	CRV FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
Valant 1	Materials and methods for modulating T-cell activity	037/0011 - Mewburn Ellis	UK	0127602.1	16/11/01	Priority
Wardman 1	Indole-3 Acetic Acid Derivatives	011/0002 - Mewburn Ellis	UK PCT	0016162.0 PCT/GB01/02872 (WO02/02110)	30/6/00 30/6/01	PCT Priority Application
Workman 2	Therapeutic compounds and their uses in therapy (HSP90)	008/0034 - Mewburn Ellis	UK	0130733.9	21/12/01	Priority
Workman 3	Assay, Methods and Means	008/0034 - Mewburn Ellis	UK	0202871.0	12/7/02	Priority


CDGP

IN WITNESS WHEREOF this Assignment has been executed as a deed by the parties' duly authorised representatives and delivered on the day and year first before written

EXECUTED as a DEED by)
CANCER RESEARCH)
TECHNOLOGY LIMITED acting by:)

KANPAL S. KAPAR
Director

CLIVE STANWAT
Director/Secretary



Clive Stanway

EXECUTED as a DEED by)
CANCER RESEARCH VENTURES)
LIMITED acting by:)

KEITH BLUNDY
Director

GEORGE PICKERING
Director/Secretary



C.D.G. Pickering